News + Filings Transactions Holdings
All
13F
13D/G
Other
|
|
Abingworth LLP
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/02/2023 |
4
| Carlyle Group Inc. (10% Owner) has filed a Form 4 on SOLENO THERAPEUTICS INC|
Txns:
| Converted 329,930 shares
@ $1.75, valued at
$577.4k
Converted 1,092,056 options to buy
@ $1.75, valued at
$1.9M
Converted 762,126 options to buy
@ $0.01, valued at
$7.6k
|
|
| 08/04/2023 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 05/10/2023 |
4
| Carlyle Group Inc. (10% Owner) has filed a Form 4 on SOLENO THERAPEUTICS INC|
Txns:
| Bought 1,092,056 options to buy
@ $1.75, valued at
$1.9M
Bought 1,778,000 options to buy
@ $2.5, valued at
$4.4M
|
|
| 05/05/2023 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 02/10/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 01/31/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/10/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 08/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/15/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 08/11/2022 |
SC 13D/A
| Abingworth LLP reports a 4.4% stake in Verona Pharma plc |
| 07/11/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 05/16/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 05/13/2022 |
SC 13G
| Abingworth LLP reports a 5.5% stake in HILLEVAX, INC. |
| 04/08/2022 |
SC 13D/A
| Abingworth LLP reports a 15.3% stake in Soleno Therapeutics Inc. |
| 04/07/2022 |
SC 13D/A
| Abingworth LLP reports a 11.1% stake in Vera Therapeutics, Inc. |
| 03/31/2022 |
4
| Abingworth LLP (10% Owner) has filed a Form 4 on SOLENO THERAPEUTICS INC|
Txns:
| Bought 7,720,000 shares
@ $0
Granted 20,000 options to buy
@ $1.57, valued at
$31.4k
Granted 13,000 options to buy
@ $2.5, valued at
$32.5k
Granted 9,530 options to buy
@ $3.41, valued at
$32.5k
Granted 40,000 options to buy
@ $2.24, valued at
$89.6k
Granted 31,862 options to buy
@ $1.02, valued at
$32.5k
Bought 7,720,000 warrants
@ $0.3, valued at
$2.3M
|
|
| 03/23/2022 |
4
| Abingworth LLP (10% Owner) has filed a Form 4 on Jasper Therapeutics, Inc.|
Txns:
| Granted 78,045 options to buy
@ $3.54, valued at
$276.3k
|
|
| 03/21/2022 |
SC 13D/A
| Abingworth LLP reports a 8.9% stake in Sierra Oncology, Inc. |
| 02/25/2022 |
SC 13D/A
| Abingworth LLP reports a 6.5% stake in Exicure, Inc. |
| 02/16/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/14/2022 |
SC 13G/A
| Abingworth LLP reports a 7.9% stake in VAXCYTE, INC. |
| 02/10/2022 |
SC 13D/A
| Abingworth LLP reports a 11.3% stake in Sierra Oncology, Inc. |
| 02/01/2022 |
4
| Abingworth LLP (10% Owner) has filed a Form 4 on Sierra Oncology, Inc.|
Txns:
| Bought 150,000 shares
@ $27, valued at
$4.1M
Exercised (in-or-at-the-money) 287,471 options to buy
@ $13.2, valued at
$3.8M
|
|
| 12/17/2021 |
4
| Abingworth LLP (10% Owner) has filed a Form 4 on eFFECTOR Therapeutics, Inc.|
Txns:
| Granted 40,000 options to buy
@ $11.36, valued at
$454.4k
|
|
| 11/15/2021 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 11/05/2021 |
3
| Abingworth LLP (10% Owner) has filed a Form 3 on Sierra Oncology, Inc. |
| 11/05/2021 |
SC 13D/A
| Abingworth LLP reports a 12.6% stake in Sierra Oncology, Inc. |
| 10/04/2021 |
SC 13D
| Abingworth LLP reports a 15.4% stake in Jasper Therapeutics, Inc. |
| 10/01/2021 |
3
| Abingworth LLP (10% Owner) has filed a Form 3 on Jasper Therapeutics, Inc. |
| 09/03/2021 |
SC 13D
| Abingworth LLP reports a 11.9% stake in eFFECTOR Therapeutics, Inc. |
| 08/27/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 08/16/2021 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 05/24/2021 |
SC 13D
| Abingworth LLP reports a 14.6% stake in Vera Therapeutics, Inc. |
| 05/18/2021 |
4
| Abingworth LLP (10% Owner) has filed a Form 4 on Vera Therapeutics, Inc.|
Txns:
| Converted 2,187,504 shares
@ $0
Bought 772,727 shares
@ $11, valued at
$8.5M
Granted 9,925 options to buy
@ $11, valued at
$109.2k
|
|
|
|
|